SEC Tracker
Get the app

ARS Pharmaceuticals SPRY

ARS Pharmaceuticals reports $35.59 million net loss

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $37.71 million for the three months ended Sep 30, 2026
  2. Net loss: $35.59 million for the three months ended Sep 30, 2026
  3. Diluted EPS: -$0.36 for the three months ended Sep 30, 2026
  4. Cash and equivalents: $25.62 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when ARS Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Spyre Therapeutics SYRE public float $1.1B, Jun 30, 2025
  2. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  3. Mannkind MNKD public float $1.1B, Jun 30, 2025
  4. Novavax NVAX public float $1.0B, Jun 30, 2025
  5. Harrow HROW public float $1.0B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.